A new round of tariffs on imported prescription drugs took effect at 12:01 a.m. Eastern on July 31, 2026, and most people who take a daily pill will not see anything change at the pharmacy counter this week. The tariff applies to patented drugs made by seventeen large drugmakers named in the government's own list, not to the generic version most patients actually pick up. That distinction matters more than almost anything else in this story. It does not mean prescription costs are frozen in place, only that the mechanism connecting a new import tax to a patient's copay runs longer and slower than headlines about tariffs usually suggest.
This piece walks through what the rule actually does and who pays it first. It also covers how long the exemption most patients currently rely on is likely to last, and what parts of the picture are still unsettled.
What took effect on July 31
The tariffs come from a presidential proclamation titled Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States, published in the Federal Register on April 9, 2026. It relies on Section 232 of a 1962 trade law, the same authority the administration has used on steel and aluminum, to declare that reliance on imported drugs and drug ingredients threatens national security.
The proclamation set a compliance window rather than a single start date. Seventeen companies named in an annex to the order became subject to the tariff on July 31, 2026. Everyone else who imports a covered drug has until September 29, 2026, according to a client alert from the law firm Crowell and Moring published July 30, 2026.
The default duty is steep. It runs 100 percent on a patented drug, or on its active pharmaceutical ingredient, if that drug is tied to a valid US patent and appears in the FDA's Orange Book or Purple Book, the agency's lists of approved drugs and the patents that cover them.
Who actually pays the tariff first
A tariff is a tax collected at the border. The importer of record pays it when the drug or ingredient crosses into the country, not the pharmacy that later hands you a bottle, and not you at the register. That is the part of this story easiest to get backwards.
From there, the cost has to travel through several layers before it reaches a patient, and it does not travel instantly. A manufacturer facing a new 100 percent duty can raise its list price to cover it. An insurer or pharmacy benefit manager then decides whether to keep that drug on a formulary at the new price or push patients toward an alternative. Only after that decision gets made does a patient's copay or coinsurance actually move. Formulary contracts typically get renegotiated on an annual cycle, not a weekly one, which adds more lag on top of whatever a manufacturer decides to do with its list price. Each step in that chain can take months, which is one reason nobody should expect a price jump on August 1.
Which drugs are actually covered
The 100 percent default rate is not the only number in play. Companies with a Commerce Department approved plan to build or expand US manufacturing pay a reduced 20 percent rate instead, one scheduled to climb back to the full 100 percent by April 2, 2030, according to the Crowell and Moring alert of July 30, 2026. Thirteen of the seventeen companies named in the order combined that onshoring commitment with a separate pricing agreement with the Department of Health and Human Services, built around a most favored nation pricing standard. Those thirteen companies pay nothing at all through January 20, 2029.
Country of origin changes the rate again. Products originating in the European Union, Japan, South Korea, or Switzerland and Liechtenstein carry a 15 percent rate. Products from the United Kingdom carry 10 percent.
Several categories sit outside this round of tariffs entirely, at least for now.
- Generic drugs and biosimilars, exempt in this round and flagged for a one year review
- Orphan drugs approved for a rare disease indication
- Cell and gene therapies
- Plasma derived products and nuclear medicines, along with a narrower set of other specified categories
Why most patients are not exposed yet
The reason this round of tariffs barely touches most people is arithmetic, not policy generosity. About 9 in 10 prescriptions filled in the United States are for generic drugs, a figure the FDA and federal health researchers have reported consistently for years. Generics are exempt from the current tariff. A retiree filling a statin or a blood pressure prescription each month is, for now, outside the tariff entirely.
That exemption has an expiration date attached to it, sort of. On July 21, 2026, the administration laid out a separate, phased tariff plan aimed specifically at generic drugs. Under that plan, generics face no tariff for two years, then a 100 percent rate beginning around August 2028, then 200 percent about a year after that, according to reporting from Bloomberg on July 21, 2026 and CNBC on July 22, 2026. Nothing in that plan is final rulemaking yet. It is a stated intention, and the two year runway is meant to give generic manufacturers time to build US plants.
Whether that timeline works is an open question. Industry estimates commonly put the share of active pharmaceutical ingredients sourced from India and China at a large majority of the US generic supply, a concentration that took decades to build and that a two year window may not undo. Generic manufacturers already operate on thin margins, closer to a commodity business than a pharmaceutical one, and a tariff large enough to force reshoring is also large enough to push a low margin product out of the US market entirely if a company decides reshoring costs more than it can recover.
What is still unknown
A few things about this rule are not settled. The generics and biosimilars exemption is explicitly under a one year review, so it could narrow before this time next year. Legal challenges to the use of Section 232 for pharmaceuticals are plausible, since courts have heard similar challenges to other Section 232 actions in recent years. The Commerce Department can also add companies to or remove them from the annexes that set each tier, so the list in effect today is not necessarily the list in effect by year end. The practical size of any price increase that eventually reaches a patient also depends on decisions individual manufacturers, insurers, and pharmacy benefit managers have not yet made public.
For someone taking a patented brand name drug with no generic equivalent, a cost increase over the next year is plausible, tied to whichever tariff tier applies to that drug's manufacturer and country of origin. For the large majority of patients on generics, the date worth watching is not July 31, 2026. It is whatever rule eventually replaces the current exemption.
This article describes tariff rules in effect as of August 1, 2026, and is general information rather than medical or legal advice. Rates, exemptions, and legal challenges are all subject to change, so check the Federal Register notice and Commerce Department guidance before assuming a rate applies to a specific drug. Questions go through our contact page.